Tusitala: William Ramirez
Aso O Foafoaga: 16 Setema 2021
Faafouga Aso: 21 Iuni 2024
Anonim
What Doctors are saying about CBD? | Cannabidiol
Ata: What Doctors are saying about CBD? | Cannabidiol

Anotusi

Cannabidiol o se vailaʻau i le Cannabis sativa plant, e taʻua foi o le mariuana poʻo le vao. E silia ma le 80 vailaʻau, ua taʻua o le cannabinoids, ua uma ona faʻailoa mai i le fale o le Cannabis sativa. E ui o le delta-9-tetrahydrocannabinol (THC) o le vaega sili lea ona aoga i le mariuana, ae o le cannabidiol e maua mai foi i le hemp, e naʻo nai vaega laiti lava o le THC e maua ai.

O le pasia o le Farm Farm 2018 na faʻatagaina ai ona faʻatau atu hemp ma hemp oloa i le U.S. Ae le o le uiga o lena mea uma hemp cannabidiol oloa e maua i le tulafono. Talu ai o le cannabidiol na aʻoaʻoina o se vailaʻau fou, e le mafai ona faʻaaofia faʻapitoa i meaʻai poʻo meaʻai faʻaopopo. E le gata i lea, e le mafai ona faʻaaogaina le cannabidiol i totonu o oloa o loʻo maketiga ma faʻamatalaga o togafitiga. Cannabidiol faʻatoa mafai ona aofia i "cosmetic" oloa ma pe a fai e aofia ai laʻititi ifo i le 0.3% THC. Ae o loʻo iai lava oloa o loʻo faʻaigoaina o meaʻai faʻaopopo i luga ole maketi o loʻo iai cannabidiol. O le aofaʻi o cannabidiol o loʻo i totonu o nei oloa e le masani ona lipotia lelei i luga o le igoa igoa.

Cannabidiol e masani ona faʻaaogaina mo seizure faʻaletonu (epilepsy). E faʻaaogaina foi mo le atuatuvale, tiga, le maʻi o le musele ua taʻua o le dystonia, Parkinson faamaʻi, Crohn faamaʻi, ma le tele o isi tulaga, ae leai se lelei faʻasaienisi faʻamaoniga e lagolagoina nei faʻaaoga.

Natura Faʻafomaʻi Maea Faʻamatalaga fua faatatau aoga faʻavae i luga o faʻasaienitisi faʻamaoniga e tusa ma le fua faʻatatau lenei: Aoga, Masalo Lelei Lelei, E Lelei Lelei, Masalo Lelei Lelei, Masalo Lelei, Le Lelei, ma Le lava Faʻamaoniga e Fuafua ai.

Le aoga togi mo CANNABIDIOL (CBD) e faapea:


Masalo aoga mo ...

  • Faʻafitauli o le faoa (epilepsy). O se oloa faapitoa cannabidiol (Epidiolex, GW Faletalavai) na faʻaalia e faʻaititia ai faʻafitauli i tagata matutua ma tamaiti ma le tele o tuutuuga e fesoʻotaʻi ma le maʻi. O lenei oloa o se vailaʻau faʻatonu mo le togafitia o faʻamaʻi e mafua mai i le Dravet syndrome, Lennox-Gastaut syndrome, poʻo le tuberous sclerosis complex. Na faʻaalia foi e faʻaititia ai le faʻamalosi o tagata i le Sturge-Weber syndrome, faʻamaʻi pipisi e fesoʻotaʻi ma le epilepsy (FIRES), ma faʻafitauli ogaoga o le tupuaga na mafua ai le epileptic encephalopathy. Ae e le faʻamaonia mo le togafitia o isi ituaiga o faʻafilemu. O lenei oloa e masani ona ave faʻatasi ma vailaʻau masani e teteʻe ai i le mafaufau. O loʻo suʻesuʻeina foi nisi o oloa cannabidiol o loʻo faia i totonu ole fale suesue mo le maʻilili. Ae e faʻatapulaʻa suʻesuʻega, ma e leai se tasi o nei oloa e faʻamaonia e avea ma vailaʻau talavai.

Le lava molimau e fuaina aoga mo ...

  • O se ituaiga o faʻamaʻi manava manava (Crohn faʻamaʻi). O le vave suʻesuʻe na faʻaalia ai o le avea o le cannabidiol e le faʻaititia ai faʻamaʻi gaioiga i tagata matutua e maua i le faʻamaʻi Crohn.
  • Maʻi suka. I le amataga o suʻesuʻega faʻaalia ai o le inuina o le cannabidiol e le faʻaleleia ai le puleaina o le kulukose o le toto i tagata matutua e maua i le maʻisuka ituaiga 2.
  • O se gasegase gaioiga na faʻailogaina e le faʻaosoina maso maso (dystonia). E le malamalama pe a fai o le cannabidiol e aoga mo le dystonia.
  • O se tofi tuufaʻailogaina faʻailoaina e le atoatoa le aʻoaʻoina (fragile- X syndrome). O suʻesuʻega muamua e taʻu mai ai o le faʻaaogaina o le cannabidiol gel atonu e faʻaititia ai le popolevale ma faʻalelei amioga i tamaiti e maua i le maʻi vaivai X.
  • O se tuutuuga e osofaʻia ai le tino e se tui (graft-versus-host disease poʻo le GVHD). Graft-versus-host disease o se faʻalavelave e mafai ona tupu pe a maeʻa le gaʻo o le ponaivi. O le amataga o suʻesuʻega na maua ai o le aveina o le cannabidiol i aso uma e amata i le 7 aso ae le i toe tui le ponaivi ma faʻaauau mo le 30 aso peʻa maeʻa le totoina e mafai ona faʻalauteleina le taimi e manaʻomia e se tagata e atiaʻe ai le GVHD.
  • O se faaletonu faiʻai tuufaasolo e aafia ai gaioiga, lagona, ma mafaufauga (Huntington faamaʻi). O le vave suʻesuʻe ua faʻaalia ai o le avea o le cannabidiol i aso uma e le faʻaleleia atili ai faʻailoga o le faʻamaʻi o Huntington.
  • Tele sclerosis (MS). O suʻesuʻega amata e faʻapea o le faʻaaogaina o le vailaʻau o le cannabidiol i lalo o le laulaufaiva e ono faʻaleleia atili ai le tiga ma le maopoopo o maso i tagata e iai le MS.
  • Aveʻese mai heroin, morphine, ma isi fualaʻau opioid. O le vave suʻesuʻe na faʻaalia ai o le avea o le cannabidiol mo le 3 aso e ono faʻaititia ai le manaʻo tele ma le popole i tagata e maua ai le faʻamaʻi o le heroin.
  • Faʻamaʻi Parkinson. O suʻesuʻega muamua na faʻaalia ai o le cannabidiol atonu e faʻaititia ai le popole ma faʻamaʻi o le mafaufau i tagata e maua i le faʻamaʻi Parkinson.
  • Schizophrenia. O le vave suʻesuʻe e taʻu mai ai o le aveina o le cannabidiol e faʻaleleia atili ai faʻailoga ma le soifua lelei i tagata e maua i le schizophrenia.
  • Tuu le ulaula. Fai mai le suʻesuʻega, o le manavaina o le cannabidiol ma le tagata e manavaina mo le vaiaso e tasi, e ono faʻaititia ai le sikaleti e ulaula e tagata ulaula o loʻo taumafai e faʻamuta.
  • O se ituaiga o popolega faʻailogaina e le fefe i nisi poʻo nofoaga uma faʻaagafesoʻotaʻi (faʻaletonu popolega lautele). I le amataga o suʻesuʻega faʻaalia ai o le cannabidiol atonu e faʻaleleia le popole i tagata e maua i lenei faʻamaʻi. Ae e le malamalama pe afai e fesoasoani faʻaititia le popolevale i le taimi o le lautele lautele tautala.
  • O se vaega o tiga tulaga e afaina ai le auvae soʻoga ma maso (faaletonu temporomandibular poʻo TMD). I le amataga o suʻesuʻega o loʻo faʻaalia ai o le faʻaaogaina o le suauʻu o loʻo iai le cannabidiol i le paʻu e ono faʻaititia ai le tiga o tagata e iai le TMD.
  • Faʻaleagaina neula i lima ma vae (peripheral neuropathy).
  • Faʻafitauli o le Bipolar.
  • Le mautonu.
  • Isi tulaga.
E tele faʻamaoniga e manaʻomia e fua ai le aoga o le cannabidiol mo nei faʻaaogaina.

Cannabidiol ei ai aʻafiaga i luga o le faiʻai. O le mafuaʻaga tonu mo nei aʻafiaga e le o manino. Ae ui i lea, o le cannabidiol e foliga mai e puipuia le malepe o se vailaʻau i le faiʻai e afaina ai le tiga, lagona, ma le mafaufau faʻagaioiga. Puipuia le malepelepe o lenei vailaʻau ma faʻateleina ona tulaga i le toto foliga mai e faʻaititia psychotic faʻailoga fesoʻotaʻi ma tulaga pei o le schizophrenia. Cannabidiol ono mafai ona poloka nisi o psychoactive aʻafiaga o le delta-9-tetrahydrocannabinol (THC). Faʻapea foi, cannabidiol foliga mai e faʻaititia le tiga ma le popole.

A ave e le gutu: Cannabidiol o MAFAI ONA SAFIA pe a ave e le gutu pe faʻasusu i lalo o le laulaufaiva talafeagai. Cannabidiol i tui e oʻo atu i le 300 mg i aso uma na ave e le gutu ma le saogalemu mo le oʻo atu i le 6 masina. Maualuga tui o 1200-1500 mg i aso uma na faia e le gutu saogalemu mo le oʻo atu i le 4 vaiaso. O le vailaʻau cannabidiol oloa (Epidiolex) ua faʻamaonia e ave e le gutu i tui e oʻo atu i le 25 mg / kg i aso uma. Cannabidiol sprays o loʻo faʻaogaina i lalo o le laulaufaiva na faʻaaogaina i tui o le 2.5 mg mo le oʻo atu i le 2 vaiaso.

O isi lipotia aafiaga itu o cannabidiol aofia gutu mago, maualalo le toto maualuga, malamalama ulu, ma le fia moe. O faʻailoga o le lavea o le ate ua lipotia mai foi i nisi tagata mamaʻi, ae o lenei e tau le masani ai.

A faʻapipiʻi i le paʻu: E le lava faʻamatalaga faʻatuatuaina e iloa ai pe o saogalemu le cannabidiol poʻo a foi ni aʻafiaga e ono i ai.

Lapataiga faʻapitoa & lapataʻiga:

Maitaga ma susu-fafagaina: Cannabidiol o E L MAFAI ONA FUA faʻaaoga pe a fai o oe o maʻito pe fafagaina susu. Cannabidiol oloa mafai ona faʻaleagaina ma isi mea e ono afaina ai le fetus poʻo le pepe. Tumau i le itu saogalemu ma aloese mai le faʻaaogaina.

Tamaiti: O le vailaʻau vailaʻau cannabidiol oloa (Epidiolex) o MAFAI ONA SAFIA pe a ave e le gutu i tui e oʻo atu i le 25 mg / kg i aso uma. Lenei oloa ua faʻamaonia mo le faʻaaogaina i nisi tamaiti 1 tausaga le matutua ma luga atu.

Maʻi ole ate: Tagata e maua i le maʻi ate ono manaʻomia le faʻaaogaina maualalo tui o cannabidiol faʻatusatusa i soifua maloloina tagata mamaʻi.

Faʻamaʻi Parkinson: O ni suʻesuʻega vave na fai mai o le inuina o tui maualuga o le cannabidiol e ono faʻatupuina ai maso ma tetete i nisi tagata e maua i le faʻamaʻi Parkinson.

Feololo
Faʻaeteete i lenei tuʻufaʻatasiga.
Brivaracetam (Briviact)
Brivaracetam ua suia ma vaevaeina e le tino. Cannabidiol ono faʻaititia le vave na tipi e le tino le brivaracetam. Lenei ono faʻateleina tulaga o brivaracetam i le tino.
Carbamazepine (Tegretol)
Carbamazepine ua suia ma vaevaeina e le tino. Cannabidiol ono faʻaititia le vave na tipi e le tino le karbamazepine. Lenei ono faʻateleina tulaga o carbamazepine i le tino ma faʻateleina ona aʻafiaga.
Clobazam (Onfi)
Clobazam ua suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia pe o le a le vave ona gagau i le ate le chebazam. Lenei ono faʻateleina ai aʻafiaga ma aʻafiaga o clobazam.
Eslicarbazepine (Aptiom)
Eslicarbazepine ua suia ma vaevaeina e le tino. Cannabidiol ono faʻaititia pe o le a le vave ona gagau e le tino le eslicarbazepine. Lenei ono faʻateleina tulaga o eslicarbazepine i le tino e se laititi.
Everolimus (Zostress)
Everolimus ua suia ma vaevaeina e le tino. Cannabidiol ono faʻaititia le vave na gagau e le tino everolimus. Lenei ono faʻateleina tulaga o everolimus i le tino.
Lithium
O le maualuga o vailaʻau o le cannabidiol atonu e faʻateleina ai le maualuga o le lithium. Lenei mafai faʻateleina le aʻafiaga o lithium oona.
O vailaʻau na suia e le ate (Cytochrome P450 1A1 (CYP1A1) substrates)
Nisi vailaʻau e suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia le vave na tipi e le ate nisi vailaʻau. I le teori, faʻaaogaina o le cannabidiol faʻatasi ai ma nisi vailaʻau e malepe i lalo e le ate ono faʻateleina ai aʻafiaga ma aʻafiaga o nisi vailaʻau. Ae e te leʻi faʻaaogaina le cannabidiol, talanoa i lau fomaʻi pe a e inu ni vailaʻau e suia e le ate.

Nisi vailaʻau suia e le ate aofia chlorzoxazone (Lorzone) ma theophylline (Theo-Dur, isi).
O vailaʻau na suia e le ate (Cytochrome P450 1A2 (CYP1A2) substrates)
Nisi vailaʻau e suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia le vave na tipi e le ate nisi vailaʻau. I le teori, faʻaaogaina o le cannabidiol faʻatasi ai ma nisi vailaʻau e malepe i lalo e le ate ono faʻateleina ai aʻafiaga ma aʻafiaga o nisi vailaʻau. Ae e te leʻi faʻaaogaina le cannabidiol, talanoa i lau fomaʻi pe a e inu ni vailaʻau e suia e le ate.

Nisi vailaʻau suia e le ate aofia amitriptyline (Elavil), haloperidol (Haldol), ondansetron (Zofran), propranolol (Inderal), theophylline (Theo-Dur, isi), verapamil (Calan, Isoptin, isi), ma isi.
O vailaʻau na suia e le ate (Cytochrome P450 1B1 (CYP1B1) substrates)
Nisi vailaʻau e suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia le vave na tipi e le ate nisi vailaʻau. I le teori, faʻaaogaina o le cannabidiol faʻatasi ai ma nisi vailaʻau e malepe i lalo e le ate ono faʻateleina ai aʻafiaga ma aʻafiaga o nisi vailaʻau. Ae e te leʻi faʻaaogaina le cannabidiol, talanoa i lau fomaʻi pe a e inuina ni vailaʻau e suia e le ate.

Nisi vailaʻau suia e le ate aofia theophylline (Theo-Dur, isi), omeprazole (Prilosec, Omesec), clozapine (Clozaril, FazaClo), progesterone (Prometrium, isi), lansoprazole (Prevacid), flutamide (Eulexin), oxaliplatin (Eloxatin ), erlotinib (Tarceva), ma le kafeini.
O vailaʻau na suia e le ate (Cytochrome P450 2A6 (CYP2A6) substrates)
Nisi vailaʻau e suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia le vave na tipi e le ate nisi vailaʻau. I le teori, faʻaaogaina o le cannabidiol faʻatasi ai ma nisi vailaʻau e malepe i lalo e le ate ono faʻateleina ai aʻafiaga ma aʻafiaga o nisi vailaʻau. Ae e te leʻi faʻaaogaina le cannabidiol, talanoa i lau fomaʻi pe a e inu ni vailaʻau e suia e le ate.

O ni vailaʻau na suia e le ate e aofia ai le nikotini, chlormethiazole (Heminevrin), coumarin, methoxyflurane (Penthrox), halothane (Fluothane), valproic acid (Depacon), disulfiram (Antabuse), ma isi.
O vailaʻau na suia e le ate (Cytochrome P450 2B6 (CYP2B6) substrates)
Nisi vailaʻau e suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia le vave na tipi e le ate nisi vailaʻau. I le teori, faʻaaogaina o le cannabidiol faʻatasi ai ma nisi vailaʻau e malepe i lalo e le ate ono faʻateleina ai aʻafiaga ma aʻafiaga o nisi vailaʻau. Ae e te leʻi faʻaaogaina le cannabidiol, talanoa i lau fomaʻi pe a e inu ni vailaʻau e suia e le ate.

Nisi vailaʻau suia e le ate aofia ketamine (Ketalar), phenobarbital, orphenadrine (Norflex), secobarbital (Seconal), ma dexamethasone (Decadron).
O vailaʻau na suia e le ate (Cytochrome P450 2C19 (CYP2C19) substrates)
Nisi vailaʻau e suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia le vave na tipi e le ate nisi vailaʻau. I le teori, faʻaaogaina o le cannabidiol faʻatasi ai ma nisi vailaʻau e malepe i lalo e le ate ono faʻateleina ai aʻafiaga ma aʻafiaga o nisi vailaʻau. Ae e te leʻi faʻaaogaina le cannabidiol, talanoa i lau fomaʻi pe a e inuina ni vailaʻau e suia e le ate.

Nisi vailaʻau suia e le ate aofia proton pamu taofiofia aofia ai omeprazole (Prilosec), lansoprazole (Prevacid), ma pantoprazole (Protonix); diazepam (Valium); carisoprodol (Soma); nelfinavir (Viracept); ma isi.
O vailaʻau na suia e le ate (Cytochrome P450 2C8 (CYP2C8) substrates)
Nisi vailaʻau e suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia le vave na tipi e le ate nisi vailaʻau. I le teori, faʻaaogaina o le cannabidiol faʻatasi ai ma nisi vailaʻau e malepe i lalo e le ate ono faʻateleina ai aʻafiaga ma aʻafiaga o nisi vailaʻau. Ae e te leʻi faʻaaogaina le cannabidiol, talanoa i lau fomaʻi pe a e inu ni vailaʻau e suia e le ate.
Nisi vailaʻau suia e le ate aofia amiodarone (Cordarone), carbamazepine (Tegretol), chloroquine (Aralen), diclofenac (Voltaren), paclitaxel (Taxol), repaglinide (Prandin) ma isi.
O vailaʻau na suia e le ate (Cytochrome P450 2C9 (CYP2C9) substrates)
Nisi vailaʻau e suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia le vave na tipi e le ate nisi vailaʻau. I le teori, faʻaaogaina o le cannabidiol faʻatasi ai ma nisi vailaʻau e malepe i lalo e le ate ono faʻateleina ai aʻafiaga ma aʻafiaga o nisi vailaʻau. Ae e te leʻi faʻaaogaina le cannabidiol, talanoa i lau fomaʻi pe a e inuina ni vailaʻau e suia e le ate.

O ni vailaʻau na suia e le ate e aofia ai fualaʻau faʻafomaʻi o le anti-inflammatory (NSAIDs) pei o le diclofenac (Cataflam, Voltaren), ibuprofen (Motrin), meloxicam (Mobic), piroxicam (Feldene), ma celecoxib (Celebrex); amitriptyline (Elavil); warfarin (Coumadin); glipizide (Glucotrol); losartan (Cozaar); ma isi.
O vailaʻau na suia e le ate (Cytochrome P450 2D6 (CYP2D6) substrates)
Nisi vailaʻau e suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia le vave na tipi e le ate nisi vailaʻau. I le teori, faʻaaogaina o le cannabidiol faʻatasi ai ma nisi vailaʻau e malepe i lalo e le ate ono faʻateleina ai aʻafiaga ma aʻafiaga o nisi vailaʻau. Ae e te leʻi faʻaaogaina le cannabidiol, talanoa i lau fomaʻi pe a e inu ni vailaʻau e suia e le ate.

Nisi vailaʻau suia e le ate aofia amitriptyline (Elavil), codeine, desipramine (Norpramin), flecainide (Tambocor), haloperidol (Haldol), imipramine (Tofranil), metoprolol (Lopressor, Toprol XL), ondansetron (Zofran), paroxetine (Paxil ), risperidone (Risperdal), tramadol (Ultram), venlafaxine (Effexor), ma isi.
O vailaʻau na suia e le ate (Cytochrome P450 3A4 (CYP3A4) substrates)
Nisi vailaʻau e suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia le vave na tipi e le ate nisi vailaʻau. I le teori, faʻaaogaina o le cannabidiol faʻatasi ai ma nisi vailaʻau e malepe i lalo e le ate ono faʻateleina ai aʻafiaga ma aʻafiaga o nisi vailaʻau. Ae e te leʻi faʻaaogaina le cannabidiol, talanoa i lau fomaʻi pe a e inuina ni vailaʻau e suia e le ate.

O ni vailaʻau na suia e le ate e aofia ai le alprazolam (Xanax), amlodipine (Norvasc), clarithromycin (Biaxin), cyclosporine (Sandimmune), erythromycin, lovastatin (Mevacor), ketoconazole (Nizoral), itraconazole (Sporanox), fexofenadine (Halcion), verapamil (Calan, Isoptin) ma le tele o isi.
O vailaʻau na suia e le ate (Cytochrome P450 3A5 (CYP3A5) substrates)
Nisi vailaʻau e suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia le vave na tipi e le ate nisi vailaʻau. I le teori, faʻaaogaina o le cannabidiol faʻatasi ai ma nisi vailaʻau e malepe i lalo e le ate ono faʻateleina ai aʻafiaga ma aʻafiaga o nisi vailaʻau. Ae e te leʻi faʻaaogaina le cannabidiol, talanoa i lau fomaʻi pe a e inuina ni vailaʻau e suia e le ate.

Nisi vailaʻau suia e le ate aofia testosterone, progesterone (Endometrin, Prometrium), nifedipine (Adalat CC, Procardia XL), cyclosporine (Sandimmune), ma isi.
Vailaau suia e le ate (Glucuronidated vailaʻau)
Nisi vailaʻau e suia ma talepeina i lalo e le ate. Cannabidiol ono faʻaititia le vave na tipi e le ate nisi vailaʻau. O le aveina o le cannabidiol faʻatasi ai ma isi vailaʻau e malepe i lalo e le ate e ono faʻateleina ai aʻafiaga ma aʻafiaga o nei vailaʻau.
O nisi o nei vailaʻau suia e le ate e aofia ai acetaminophen (Tylenol, isi) ma oxazepam (Serax), haloperidol (Haldol), lamotrigine (Lamictal), morphine (MS Contin, Roxanol), zidovudine (AZT, Retrovir), ma isi.
O vailaʻau e faʻaititia ai le malepe o isi vailaʻau ile ate (Cytochrome P450 2C19 (CYP2C19) taofiofia)
Cannabidiol e malepe i lalo e le ate. Nisi vailaʻau ono faʻaititia pe faʻapefea ona vave gagau i le ate le cannabidiol. O le aveina o le cannabidiol faʻatasi ma nei vailaʻau ono faʻateleina ai aʻafiaga ma aʻafiaga o le cannabidiol.
Nisi vailaʻau e ono faʻaititia ai le malepe cannabidiol i le ate aofia cimetidine (Tagamet), fluvoxamine (Luvox), omeprazole (Prilosec); ticlopidine (Ticlid), topiramate (Topamax), ma isi.
O vailaʻau e faʻaititia ai le malepe o isi vailaʻau ile ate (Cytochrome P450 3A4 (CYP3A4) taofiofia)
Cannabidiol e malepe i lalo e le ate. Nisi vailaʻau ono faʻaititia pe faʻapefea ona vave gagau i le ate le cannabidiol. O le aveina o le cannabidiol faʻatasi ma nei vailaʻau ono faʻateleina ai aʻafiaga ma aʻafiaga o le cannabidiol.
O ni vailaʻau e ono faʻaititia ai le vave o le pa o le ate i lalo cannabidiol aofia amiodarone (Cordarone), clarithromycin (Biaxin), diltiazem (Cardizem), erythromycin (E-mycin, Erythrocin), indinavir (Crixivan), ritonavir (Norvir), saquinavir (Fortovase , Invirase), ma le tele o isi.
O vailaʻau e faʻateleina ai le malepe o isi vailaʻau ile ate (Cytochrome P450 3A4 (CYP3A4) faʻamalosiʻau)
Cannabidiol e malepe i lalo e le ate. Nisi vailaʻau ono faʻateleina le vave ona gagau e le ate le cannabidiol. O le aveina o le cannabidiol faʻatasi ai ma nei vailaʻau ono faʻaititia ai aafiaga o le cannabidiol.
O nisi o nei vailaʻau e aofia ai carbamazepine (Tegretol), phenobarbital, phenytoin (Dilantin), rifampin, rifabutin (Mycobutin), ma isi.
O vailaʻau e faʻateleina ai le malepe o isi vailaʻau ile ate (Cytochrome P450 2C19 (CYP2C19) faʻatosinaina)
Cannabidiol e malepe i lalo e le ate. Nisi vailaʻau ono faʻateleina le vave ona gagau e le ate le cannabidiol. O le aveina o le cannabidiol faʻatasi ai ma nei vailaʻau ono faʻaititia ai aafiaga o le cannabidiol.
O ni vailaʻau e ono faʻateleina ai le malepelepe o le cannabidiol i le ate e aofia ai le carbamazepine (Tegretol), prednisone (Deltasone), ma le rifampin (Rifadin, Rimactane).
Methadone (Dolophine)
Methadone e malepe i lalo e le ate. Cannabidiol ono faʻaititia le vave na gagau e le ate le methadone. Avea cannabidiol faʻatasi ai ma le methadone ono faʻateleina ai aʻafiaga ma aʻafiaga o le methadone.
Rufinamide (Banzel)
Rufinamide ua suia ma vaevaeina e le tino. Cannabidiol ono faʻaititia le vave na tipi e le tino le rufinamide. Lenei ono faʻateleina tulaga o rufinamide i le tino e se laititi.
Vailaau faʻamalieina (CNS depressants)
Cannabidiol ono mafua ai le moe ma le fia moe. O vailaʻau e mafua ai le fia moe ua taʻua o ni vailaau faʻamalieina. O le aveina o le cannabidiol faʻatasi ai ma vailaʻau faʻafofilemu e ono mafua ai le tele o le moe.

O nisi vailaʻau faʻamalieina e aofia ai benzodiazepines, pentobarbital (Nembutal), phenobarbital (Luminal), secobarbital (Seconal), thiopental (Pentothal), fentanyl (Duragesic, Sublimaze), morphine, propofol (Diprivan), ma isi.
Sirolimus (Rapamune)
Sirolimus ua suia ma vaevaeina e le tino. Cannabidiol ono faʻaititia le vave o le tino malepe sirolimus. Lenei ono faʻateleina tulaga o sirolimus i le tino.
Stiripentol (Diacomit)
Stiripentol ua suia ma vaevaeina e le tino. Cannabidiol ono faʻaititia pe o le a le vave ona gagau e le tino le stimipentol. Lenei ono faʻateleina tulaga o le stimipentol i le tino ma faʻateleina ona aʻafiaga.
Tacrolimus (Ata)
Tacrolimus ua suia ma vaevaeina e le tino. Cannabidiol ono faʻaititia le vave na tipi e le tino tacrolimus. Lenei ono faʻateleina tulaga o tacrolimus i le tino.
Topiramate (Tompamax)
Topiramate ua suia ma vaevaeina e le tino. Cannabidiol ono faʻaititia pe o le a le vave o le tino e talepe i lalo le topiramate. Lenei ono faʻateleina tulaga o topiramate i le tino e se laʻititi.
Valproate
Valproic acid e mafai ona mafua ai le manua o le ate. Avea cannabidiol ma valproic acid ono faʻateleina le avanoa o le ate manuʻa. Cannabidiol ma / pe valproic acid ono manaʻomia e taofi, pe ono tatau ona faʻaititia le fualaʻau.
Warfarin
Cannabidiol ono faʻateleina tulaga o warfarin, lea e mafai ona faʻateleina ai le ono maua mo le palapala. Cannabidiol ma / poʻo warfarin ono manaʻomia e taofi, pe ono faʻaititia le tui.
Zonisamide
Zonisamide ua suia ma vaevaeina e le tino. Cannabidiol ono faʻaititia le vave o le tino malepe i lalo zonisamide. Lenei ono faʻateleina tulaga o le zonisamide i le tino e se laʻititi.
Laʻau ma mea faʻaopopo ma mea faʻafilemu
Cannabidiol mafai mafua mafua moe poʻo le fia moe. Faʻaaogaina faʻatasi ma isi laʻau ma fualaʻau e tutusa a latou aʻafiaga ono mafua ai tele le moe. O nisi o nei vailaʻau ma mea faʻapipiʻi e aofia ai le calamus, California poppy, catnip, hops, Jamaican dogwood, kava, L-tryptophan, melatonin, sage, SAMe, St. John's wort, sassafras, skullcap, ma isi.
Ava Malosi (Ethanol)
Avea cannabidiol ma le ava malosi faʻateleina le aofaʻi o cannabidiol e mitiia e le tino. Lenei ono faʻateleina ai aʻafiaga ma aʻafiaga o cannabidiol.
Gaʻo ma meaʻai lololo
Aveina cannabidiol ma se taumafataga e maualuga i le gaʻo pe sili atu aofia ai ni gaʻo, faʻateleina le aofaʻi o cannabidiol e mitiia e le tino. Lenei ono faʻateleina ai aʻafiaga ma aʻafiaga o le cannabidiol.
Susu
Avea cannabidiol ma susu faʻateleina le aofaʻi o cannabidiol e mitiia e le tino. Lenei ono faʻateleina ai aʻafiaga ma aʻafiaga o cannabidiol.
O vailaʻau nei sa suʻesuʻeina i suʻesuʻega faasaienisi.

MATUTUA

E SAUNIU:
  • Mo le maʻilili: Ua faʻaoga se vailaʻau cannabidiol oloa (Epidiolex). O le fualaʻau amata fautuaina mo le Lennox-Gastaut syndrome ma le Dravet syndrome e 2.5 mg / kg faʻalua i aso uma (5 mg / kg / aso). A maeʻa le vaiaso e tasi e mafai ona faʻateleina le vailaʻau ile 5 mg / kg faʻalua i aso uma (10 mg / kg / aso). Afai e le tali mai le tagata i lenei vailaʻau, o le maualuga fautuaina o le 10 mg / kg faʻalua i aso uma (20 mg / kg / aso). O le fualaʻau amata fautuaina mo tuberous sclerosis complex o le 2.5 mg / kg faalua i aso uma (5 mg / kg / aso). Lenei mafai ona faʻateleina i vaiaso taʻitasi pe a manaʻomia, oʻo atu i le maualuga o le 12.5 mg / kg faʻalua i aso uma (25 mg / kg / aso). E leai se malosi faʻasaienisi faʻamaoniga o le le faʻatonuina o oloa cannabidiol e aoga mo epilepsy.
FANAU

E SAUNIU:
  • Mo le maʻilili: Ua faʻaoga se vailaʻau cannabidiol oloa (Epidiolex). O le fualaʻau amata fautuaina mo Lennox-Gastaut syndrome ma le Dravet syndrome o le 2.5 mg / kg faalua i aso uma (5 mg / kg / aso). A maeʻa le vaiaso e tasi e mafai ona faʻateleina le vailaʻau ile 5 mg / kg faʻalua i aso uma (10 mg / kg / aso). Afai e le tali mai le tagata i lenei vailaʻau, o le maualuga fautuaina o le 10 mg / kg faʻalua i aso uma (20 mg / kg / aso). O le fualaʻau amata fautuaina mo tuberous sclerosis complex o le 2.5 mg / kg faalua i aso uma (5 mg / kg / aso). Lenei mafai ona faʻateleina i vaiaso taʻitasi pe a manaʻomia, oʻo atu i le maualuga o le 12.5 mg / kg faʻalua i aso uma (25 mg / kg / aso). E leai se malosi faʻasaienisi faʻamaoniga o le le faʻatonuina o oloa cannabidiol e aoga mo epilepsy.
2 - [(1R, 6R) -3-Methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl] -5-pentylbenzene-1,3-diol, CBD.

Ina ia aoao atili e uiga i le auala na tusia ai lenei tusitusiga, faʻamolemole vaʻai i le Natura Faʻafomaʻi Maea Faʻamatalaga metotia


  1. Singh RK, Dillon B, Tatum DA, Van Poppel KC, Bonthius DJ. Fesuaiga-Fualaʻau Faʻafesoʻotaiga i le va o Cannabidiol ma Lithium. Tamaititi Neurol Tatala. 2020; 7: 2329048X20947896. Vaʻai faʻamatala.
  2. Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A. Pharmacokinetic suʻesuʻega o synthetic cannabidiol oral formulated i soifua maloloina volenitia. Eur J Pharm Biopharm. 2020; 154: 108-115. Vaʻai faʻamatala.
  3. Gurley BJ, Murphy TP, Gul W, Walker LA, ElSohly M. Content versus Label Claims i Cannabidiol (CBD) -o loʻo aofia ai oloa maua mai i pisinisi faʻatau i le Setete o Misisipi. J Meaʻai Meaʻai. 2020; 17: 599-607. Vaʻai faʻamatala.
  4. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) o se Fesoʻotaʻiga Faʻapitoa i Schizophrenia: O Se Multicenter Faʻataʻaliaina Faʻataʻitaʻiina Faʻataʻitaʻiga Ami J Psychiatry. 2018; 175: 225-231. Vaʻai faʻamatala.
  5. Cortopassi J. Warfarin vailaʻau fetuʻutuʻunaʻi manaʻomia ina ua uma cannabidiol amataina ma titration. Am J Soifua Maloloina Syst Pharm. 2020; 77: 1846-1851. Vaʻai faʻamatala.
  6. Bloomfield MAP, Green SF, Hindocha C, et al. Aʻafiaga o matuiʻa cannabidiol i luga o le toto o le toto ma lona fesoʻotaʻiga ma manatuaina: O le arterial spin labeling magnet resonance imaging study. J Psychopharmacol. 2020; 34: 981-989. Vaʻai faʻamatala.
  7. Wang GS, Bourne DWA, Klawitter J, et al. Lafoaia o Oral Cannabidiol-Rich Cannabis Extracks i Tamaiti ma le Epilepsy. Falemai Togafitiga. 2020. Vaʻai faʻamatala.
  8. Taylor L, Crockett J, Tayo B, Checketts D, Sommerville K. Faʻafuaseʻi ona aveʻesea le cannabidiol (CBD): O se faʻataʻitaʻiga le faʻataʻitaʻia. Epilepsy Behav. 2020; 104 (Pt A): 106938. Vaʻai faʻamatala.
  9. McNamara NA, Dang LT, Sturza J, et al. Thrombositopenia i tamaiti tamaiti gasegase i luga o le cannabidiol ma valproic acid. Epilepsia. 2020. Vaʻai faʻamatala.
  10. Rianprakaisang T, Gerona R, Hendrickson RG. Suauʻu cannabidiol faʻapisinisi faʻaleagaina ma le vailaʻau cannabinoid AB-FUBINACA tuʻuina atu i se tamaiti gasegase. Clin Toxicol (Phila). 2020; 58: 215-216. Vaʻai faʻamatala.
  11. Morrison G, Crockett J, Blakey G, Sommerville K. O le Vaega 1, Open-Label, Pharmacokinetic Trial e suʻesuʻe ai Faʻafesoʻotaʻiga Fomaʻi-Fualaʻau Faʻafitauli i le va o Clobazam, Stiripentol, poʻo Valproate ma Cannabidiol i Soifua Maloloina Mataupu. Clin Pharmacol Fualaʻau Dev. 2019; 8: 1009-1031. Vaʻai faʻamatala.
  12. Miller I, Scheffer IE, Gunning B, et al. Dose-Ranging Effect of Adjunction Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: O se Fuafuaina Togafitiga Togafitiga. JAMA Neurol. 2020; 77: 613-621. Vaʻai faʻamatala.
  13. Lattanzi S, Trinka E, Striano P, et al. Cannabidiol aoga ma le clobazam tulaga: O se faʻavasega iloiloga ma meta-auiliiliga. Epilepsia. 2020; 61: 1090-1098. Vaʻai faʻamatala.
  14. Hobbs JM, Vazquez AR, Remijan ND, et al. Suʻesuʻega o vailaʻauʻau ma vailaʻau e teteʻe ai i le mafaufau i mea lelei e lua i le au matutua soifua maloloina. Phytother Res. 2020; 34: 1696-1703. Vaʻai faʻamatala.
  15. Ebrahimi-Fakhari D, Agricola KD, Tudor C, Krueger D, Franz DN. Cannabidiol Faʻateleina Manulauti Faʻatatau o Rapamycin Inhibitor Laʻasaga i Tagata Maʻi Ma Tuberous Sclerosis Faigata. Pediatr Neurol. 2020; 105: 59-61. Vaʻai faʻamatala.
  16. de Carvalho Reis R, Almeida KJ, da Silva Lope L, de Melo Mendes CM, Bor-Seng-Shu E. Malosiaga ma talaaga leaga o le cannabidiol ma vailaʻau vailaʻau mo togafitiga-teteʻe epilepsy: Iloilo faʻasolosolo ma meta-auiliiliga. Epilepsy Behav. 2020; 102: 106635. Vaʻai faʻamatala.
  17. Darweesh RS, Khamis TN, El-Elimat T. O le aafiaga o le cannabidiol i luga o vailaʻau vailaʻau o le carbamazepine i isumu. Naunyn Schmiedebergs Arch Pharmacol. 2020. Vaʻai faʻamatala.
  18. Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. O le vaega 1, faʻasolosolo, faʻataʻitaʻi vailaʻau o le aʻafiaga o fatuga eseʻesega, susu atoa, ma le 'ava malosi i le faʻaaogaina o le cannabidiol ma le saogalemu i mataupu maloloina. Epilepsia. 2020; 61: 267-277. Vaʻai faʻamatala.
  19. Chesney E, Oliver D, Green A, et al. Aʻafiaga leaga o le cannabidiol: o se faʻavasega iloiloga ma meta-auiliiliga o faʻafomaʻi falemaʻi tofotofoga. Neuropsychopharmacology. 2020. Vaʻai faʻamatala.
  20. Ben-Menachem E, Gunning B, Arenas Cabrera CM, et al. O le Vaega II Faʻataʻitaʻiga Faʻataʻitaʻi e Suʻesuʻe ai le Malosiaga mo Vailaʻau Faʻasaina o Vailaʻau Faʻasaina ma le Stiripentol poʻo le Valproate pe a tuʻufaʻatasia ma Cannabidiol i Tagata Maʻi ma le Epilepsy. Vailaau CNS. 2020; 34: 661-672. Vaʻai faʻamatala.
  21. Bass J, Linz DR. O se Mataupu o le Toʻasa mai le Cannabidiol Gummy Ingestion. Cureus. 2020; 12: e7688. Vaʻai faʻamatala.
  22. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol ma le (-) Delta9-tetrahydrocannabinol o ni vailaʻau e puipuia ai le neuro. Faʻataʻitaʻiga Natl Acad Sci U S A. 1998; 95: 8268-73. Vaʻai faʻamatala.
  23. Hacke ACM, Lima D, de Costa F, et al. Faʻataʻitaʻiga o gaioiga a le antioxidant o le [delta] -tetrahydrocannabinol ma le cannabidiol i vaega o Cannabis sativa. Tagata suʻesuʻe 2019; 144: 4952-4961. Vaʻai faʻamatala.
  24. Madden K, Tanco K, Bruera E. Faʻafitauli taua o vailaʻau-fualaʻau i le va o Methadone ma Cannabidiol. Pediatrics. 2020; e20193256. Vaʻai faʻamatala.
  25. Hazekamp A. O le faʻafitauli i le suauʻu CBD. Med Cannabis Cannabinoids. 2018 Iuni; 1: 65-72.
  26. Xu DH, Cullen BD, Tang M, Fang Y. Le aoga o le suauʻu Cannabidiol Suauu i Symptomatic Fesoasoani o Peripheral Neuropathy o le Lower Extremities. Curr Pharm Biotechnol. 2019 Tesema 1. Vaʻai faʻamatala.
  27. de Faria SM, de Morais Fabrício D, Tumas V, et al. Aʻafiaga o le matuia o le cannabidiol pulega i luga o le popole ma gatete na mafua mai i le Simulated Public Speaking Test i tagata mamaʻi ma le faʻamaʻi Parkinson. J Psychopharmacol. 2020 Ian 7: 269881119895536. Vaʻai faʻamatala.
  28. Nitecka-Buchta A, Nowak-Wachol A, Wachol K, et al. Myorelaxant Aafiaga o Transdermal Cannabidiol Talosaga i Tagata Maʻi ma TMD: O Se Faʻatusatusaga, Faʻalua-Tauaso Faʻataʻitaʻiga. J Clin Med. 2019 Nov 6; 8. pii: E1886. Vaʻai faʻamatala.
  29. Masataka N. Anxiolytic Aʻafiaga o Toefaʻafouina Cannabidiol Togafitiga i Talavou Ma Faʻaletonu Mafatiaga Faʻaletonu. Luma Psychol. 2019 Nov 8; 10: 2466. Vaʻai faʻamatala.
  30. Appiah-Kusi E, Petros N, Wilson R, et al. Aʻafiaga o le puʻupuʻu cannabidiol togafitiga i le tali atu i faʻafitauli lautele i mataupu i falemaʻi maualuga lamatiaga o le atiaʻe psychosis. Psychopharmacology (Berl). 2020 Ian 8. Vaʻai faʻamatala.
  31. Hussain SA, Dlugos DJ, Cilio MR, Parikh N, Oh A, Sankar R. Synthetic pharmaceutment grade cannabidiol mo le togafitia o gasegase o tamaiti laiti: O le multicenter vaega-2 suʻesuʻega. Epilepsy Behav. 2020 Ian; 102: 106826. Vaʻai faʻamatala.
  32. Klotz KA, Grob D, Hirsch M, Metternich B, Schulze-Bonhage A, Jacobs J. Malosiaga ma le Faʻapalepaleina o Synthetic Cannabidiol mo Togafitiga o le Faʻafitauli o Vailaʻau Faʻafitauli. Luma Neurol. 2019 Tes 10; 10: 1313. Vaʻai faʻamatala.
  33. "GW Fale Faʻafomai plc ma Ana U.S. Subsidiary Greenwich Biosciences, Inc. Faʻasalalau Faʻapea O EPIDIOLEX® (cannabidiol) Tautala Tautala Ua Faʻatulagaina Ma Ua Le toe Avea Ma Se Mea Faʻatonutonu." GW Faletalavai, 6 Aperila 2020. http://ir.gwpharm.com/node/11356/pdf. Faʻasalalauga
  34. Wiemer-Kruel A, Stiller B, Bast T. Cannabidiol Fesoʻotaʻiga Taua ma Everolimus-Lipoti o se Tagata Maʻi ma Tuberous Sclerosis Complex. Neuropediatrics. 2019. Vaʻai faʻapitoa.
  35. FDA Tagata Faʻatau Faʻafouina: O le a le mea e tatau ona e iloa e uiga i le faʻaaogaina o Cannabis, e aofia ai le CBD, Pe a maitaga pe faʻasusu. U. S. Meaʻai ma Vailaau Faʻataʻitaʻi (FDA). Oketopa 2019. Avanoa i: https://www.fda.gov/consumers/consumer-updates/what-you-should- know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding.
  36. Taylor L, Crockett J, Tayo B, Morrison G. O le Vaega 1, Open-Label, Parallel-Group, Nofofua-Faʻataʻitaʻiga Faʻataʻitaʻiga o le Pharmacokinetics ma le Saogalemuina o Cannabidiol (CBD) i Mataupu ma Agamalu ma Matuia Hepatic Faʻaletonu. J Clin Pharmacol. 2019; 59: 1110-1119. Vaʻai faʻamatala.
  37. Szaflarski JP, Hernando K, Bebin EM, et al. Ole maualuga ole maualuga ole cannabidiol plasma e fesoʻotaʻi ma le sili atu le puʻeina o tali pe a maeʻa togafitiga ma le vailaʻau vasega cannabidiol. Epilepsy Behav. 2019; 95: 131-136. Vaʻai faʻamatala.
  38. Pretzsch CM, Voinescu B, Mendez MA, et al. O le aʻafiaga o le cannabidiol (CBD) i luga o le maualalo o taimi o gaoioiga ma fesoʻotaʻiga i le faiʻai o tagata matutua ma le leai o se faʻamaʻi o le autism (ASD). J Psychopharmacol. 2019: 269881119858306. Vaʻai faʻamatala.
  39. Pretzsch CM, Freyberg J, Voinescu B, et al. Aʻafiaga o cannabidiol i luga o le faiʻai faʻaosofia ma taofiofi sisitema; o le faʻasolosolo placebo-pulea tasi fualaʻau faʻataʻitaʻiga i le taimi o le maneta resonance spectroscopy i tagata matutua ma ma aunoa ma le autism fusi faʻapitoa Neuropsychopharmacology. 2019; 44: 1398-1405. Vaʻai faʻamatala.
  40. Patrician A, Versic-Bratincevic M, Mijacika T, et al. Suʻesuʻega o se Auala Fou mo le Faʻaooina Atu o le Tautala mo le Tautala i Mataupu Soifua Maloloina: O Se Suʻesuʻega, Faʻalua-Tauaso, Placebo-Faʻatonutonuina o le Farmacokinetics. Fautua Ther. 2019. Vaʻai faʻamatala.
  41. Martin RC, Gaston TE, Thompson M, et al. Faʻaaogaina gaioiga mulimuli ane umi taimi faʻaaoga cannabidiol i tagata matutua ma togafitiga-tetee epilepsy. Epilepsy Behav. 2019; 97: 105-110. Vaʻai faʻamatala.
  42. Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Faʻamaoniga o se falemai taua taua fualaʻau-faʻafesoʻotaʻi va i le va o le cannabidiol ma le tacrolimus. Am J Fetuunaiga. 2019; 19: 2944-2948. Vaʻai faʻamatala.
  43. Laux LC, Bebin EM, Checketts D, et al. Laveaʻi saogalemu ma aoga o cannabidiol i tamaiti ma tagata matutua ma togafitiga tetee Lennox-Gastaut syndrome poʻo Dravet syndrome: Faalauteleina avanoa polokalama taunuʻuga. Epilepsy Res. 2019; 154: 13-20. Vaʻai faʻamatala.
  44. Knaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schön C. A Novel-Emulsifying Drug Delivery System (SEDDS) Faʻavae i luga ole VESIsorb Formulate Technology Faʻaleleia le Oral Bioavailability o Cannabidiol i Soifua Maloloina mataupu. Molecules. 2019; 24. pii: E2967. Vaʻai faʻamatala.
  45. Klotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J. Aafiaga o le cannabidiol i le maualuga o le plasma brivaracetam. Epilepsia. 2019; 60: e74-e77. Vaʻai faʻamatala.
  46. Heussler H, Cohen J, Silove N, et al. O le vaega 1/2, faʻavasegaga faʻailoga iloiloga o le saogalemu, faʻapalepaleina, ma le aoga o transdermal cannabidiol (ZYN002) mo le togafitia o tamaititi maaleale X syndrome. J Neurodev Faʻaletonu. 2019; 11:16. Vaʻai faʻamatala.
  47. Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O'Sullivan SE. Palmitoylethanolamide ma Cannabidiol Puipui Fula-faʻaosoina Hyperpermeability o le Tagata Gut I Vitro ma I Vivo-A Faʻatusalia, Placebo-faʻatonutonu, Faʻalua-tauaso Faʻataʻitaʻia Faʻataʻitaʻiga. Inflamm bowel Dis. 2019; 25: 1006-1018. Vaʻai faʻamatala.
  48. Birnbaum AK, Karanam A, Marino SE, et al. Meaʻai i fualaʻau faʻasaina o le cannabidiol oral capsules i tagata matutua e maua i le maʻi o le toto. Epilepsia. 2019 Aokuso; 60: 1586-1592. Vaʻai faʻamatala.
  49. Arkell TR, Lintzeris N, Kevin RC, et al. Cannabidiol (CBD) mea i totonu o le vailaʻau oona e le mafai ona taofia ai le tetrahydrocannabinol (THC) -ʻafia ai le faʻaleagaina o le avetaʻavale ma le malamalama. Psychopharmacology (Berl). 2019; 236: 2713-2724. Vaʻai faʻamatala.
  50. Anderson LL, Apisaloma NL, Abelev SV, et al. Coadministred cannabidiol ma clobazam: Faʻamaoniga talafeagai mo uma fegalegaleai vailaʻau ma vailaʻau ma vailaʻau. Epilepsia. 2019. Vaʻai faʻamatala.
  51. Oloa faʻamatalaga mo Marinol. AbbVie. North Chicago, IL 60064. Aukuso 2017.Avanoa i: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf.
  52. Epidiolex (cannabidiol) faʻamatalaina faʻamatalaga. Greenwich Biosciences, Inc., Carlsbad, CA, 2019. Avanoa i le: https://www.epidiolex.com/site/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf (ulufale i le 5/9/2019)
  53. Faʻamatalaga mai le Komesina o le FDA o Scot Gottlieb, M.D., i le sainia o le Tulafono e Faʻaleleia ai Faʻatoʻaga ma le tulafono faʻatonutonu o oloa o loʻo i ai vailaʻau na maua mai i le cannabis Uepisaite a le U.S. Food and Drug Administration. Avanoa i: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agric Culture-improvement-act-and-agencys. (Avanoa ia Me 7, 2019).
  54. Tulafono Faʻaleleia o Faʻatoʻaga, S. 10113, 115th Cong. poʻo le S. 12619, 115th Cong. .
  55. Faʻamalosia le Faʻamalosia o Vailaau, Matagaluega o Faʻamasinoga. Faʻasologa o Vailaʻau Faʻatonutonu: Tuʻuina i le Faʻamatalaga V o Nisi Fualaʻau Faʻamaonia e le FDA O loʻo iai Cannabidiol; Suʻesuʻega e Uiga i pemita manaʻoga. Faʻatonuga mulimuli. Fed Regist. 2018 Sep 28; 83: 48950-3. Vaʻai faʻamatala.
  56. Schoedel KA, Szeto I, Setnik B, et al. Suʻesuʻe gafatia iloiloga o cannabidiol (CBD) i faʻafiafia polydrug tagata faʻaoga: O se randomized, lua-tauaso, pulea faʻataʻitaʻiga. Epilepsy Behav. 2018 Nov; 88: 162-171. fai: 10.1016 / j.yebeh.2018.07.027. Epub 2018 Oketopa 2. Vaʻaia faʻavaʻa.
  57. Devinsky O, Verducci C, Thiele EA, et al. Faʻaaoga-faʻaaogaina o le maualuga faʻamamaina CBD (Epidiolex®) i tagata mamaʻi ma CDKL5 le atoatoa le atoatoa ma Aicardi, Dup15q, ma Doose syndromes. Epilepsy Behav. 2018 Sep; 86: 131-137. Epub 2018 Iulai 11. Vaʻaia faʻavaʻa.
  58. Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, et al. Cannabidiol faʻaleleia le alualu i luma ma le ogaoga o faoa ma faʻaititia le leaga mea na tutupu i se matala-faʻaopopo faʻaopoopoga i luga o le lumanaʻi suʻesuʻega. Epilepsy Behav. 2018 Oketopa; 87: 131-136. Epub 2018 Aug 9. Seʻi vaʻaia.
  59. Linares IM, Zuardi AW, Pereira LC, et al. Cannabidiol o loʻo faʻaalia ai le feliuaʻi o U-foliga fuataga-tali i le suʻega faʻataʻitaʻi i tagata lautele. Braz J Fomaʻi. 2019 Ian-Fepuari; 41: 9-14. Epub 2018 Oketopa 11.
  60. Poklis JL, Mulder HA, Filemu MR. Le faʻailoaina le iloa o le cannabimimetic, 5F-ADB, ma le dextromethorphan i avanoa faʻatau atu cannabidiol e-suavai. Forensic Sci Int. 2019 Ian; 294: e25-e27. Epub 2018 Nov 1. Vaʻai faʻamatala.
  61. Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol mo le faʻaititia o le manaʻoga faʻaosofia o le manaʻoga ma le popole i tagata faʻafuaseʻi i fualaʻau ma Heroin Faʻaaoga le faʻaletonu: O le Faʻalua-Tauaso Faʻatusatusa Placebo-Faʻataʻitaʻia Faʻataʻitaʻiga. Am J Fomaʻi. 2019: appiajp201918101191. Vaʻai faʻamatala.
  62. Thiele EA, Marsh ED, French JA, et al. Cannabidiol i tagata mamaʻi ma faʻataʻitaʻi e fesoʻotaʻi ma Lennox-Gastaut syndrome (GWPCARE4): o se faʻasolosolo, faʻalua-tauaso, placebo-pulea vaega 3 tofotofoga. Lancet 2018 Mati 17; 391: 1085-1096. Vaʻai faʻamatala.
  63. Devinsky O, Patel AD, Cross JH, et al. Aʻafiaga o Cannabidiol i luga o Faʻaputuga Faʻamalosi i le Lennox-Gastaut Syndrome. N Engl J Med. 2018 Me 17; 378: 1888-1897. Vaʻai faʻamatala.
  64. Pavlovic R, Nenna G, Calvi L, et al. Uiga lelei o le "Suauʻu Cannabidiol": Cannabinoids Aano, Terpene Fingerprint ma le Ova Malosi o le Mautinoa o Sauniuniga Faʻatau a Europa. Molecules. 2018 Me 20; 23. pii: E1230. Vaʻai faʻamatala.
  65. Jannasch F, Kröger J, Schulze MB. Mamanu Meaʻai ma Ituaiga 2 Diabetes: O Se Faʻamaumauga Lomiga Faʻatonutonu ma Meta-Suʻesuʻega o Vaʻai Suesuega. J Nutr. 2017 Iuni; 147: 1174-1182. Vaʻai faʻamatala.
  66. Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol e saogalemu ae le aoga ile togafitia ole Crohn's Disease, ose faʻatonutonuina ole faʻataʻitaʻiina ole faʻamasinoga. Dig Dis Sci. 2017 Iuni; 62: 1615-20. Vaʻai faʻamatala.
  67. Kaplan EH, Offermann EA, Sievers JW, Comi AM. Togafitiga Cannabidiol mo faʻalavelave faʻafuaseʻi i Sturge-Weber Syndrome. Pediatr Neurol. 2017 Jun; 71: 18-23.e2. Vaʻai faʻamatala.
  68. Yeshurun ​​M, Shpilberg O, Herscovici C, et al. Cannabidiol mo le puipuia o graft-versus-host-faamaʻi i tua atu o le allogeneic hematopoietic cell transplantation: iʻuga o le vaega II suʻesuʻega. Tuiina o le Brow Blood Marrow 2015 Oketopa; 21: 1770-5. Vaʻai faʻamatala.
  69. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Faʻafesoʻotaʻiga o fualaʻau faʻasaina i le va o le clobazam ma le cannabidiol i tamaiti e maua i le maʻilili. Epilepsia. 2015 Aug; 56: 1246-51. Vaʻai faʻamatala.
  70. Devinsky O, Marsh E, Friedman D, et la. Cannabidiol i tagata mamaʻi ma epilepsy e le mafai ona togafitia ile togafitiga: o se faʻamasinoga faʻapitoa e faʻamasinoina. Lancet Neurol. 2016 Mati; 15: 270-8. Vaʻai faʻamatala.
  71. 97021 Jadoon KA, Ratcliffe SH, Barrett DA, et al. Malosiaga ma le saogalemu o le cannabidiol ma tetrahydrocannabivarin luga glycemic ma lipid faataatiaga i tagata mamaʻi ma le ituaiga 2 maʻisuka: a randomized, lua-tauaso, placebo-pulea, tutusa vaega pailate suesuega. Maʻi suka. 2016 Oketopa; 39: 1777-86. Vaʻai faʻamatala.
  72. Gofshteyn JS, Wilfong A, Devinsky O, et al. Cannabidiol o se mafai togafitiga mo febrile faʻamaʻi-fesoʻotaʻi epilepsy syndrome (FIRES) i le matuitui ma tumau vaega. J Tamaititi Neurol. 2017 Ian; 32: 35-40. Vaʻai faʻamatala.
  73. Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol o se fou togafitiga mo vailaʻau-tetee epilepsy i tuberous sclerosis faigata. Epilepsia. 2016 Oketopa; 57: 1617-24.
  74. Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; Polokalame UAB CBD. Fegalegaleaiga i le va o cannabidiol ma masani ona faʻaaogaina vailaʻau antiepileptic. Epilepsia. 2017 Sep; 58: 1586-92. Vaʻai faʻamatala.
  75. Devinsky O, Cross JH, Laux L, et al. Faʻataʻitaʻiga o le cannabidiol mo faʻamalosi e teteʻe i fualaʻau i le Dravet Syndrome. N Engl J Med. 2017 Me 25; 376: 2011-2020. Vaʻai faʻamatala.
  76. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Faʻailogaina o igoa o vailaʻau o le cannabidiol faʻatau atu i luga ole laiga. JAMA 2017 Nov; 318: 1708-9. Vaʻai faʻamatala.
  77. Malfait AM, Gallily R, Sumariwalla PF, et al. O le non-psychoactive cannabis-constituent cannabidiol o se gutu anti-arthritic togafitiga i murine collagen-faʻaosofia gugu. Faʻataʻitaʻiga Natl Acad Sci USA 2000; 97: 9561-6. Vaʻai faʻamatala.
  78. Formukong EA, Evans AT, Evans FJ. Gaioiga faʻasolosolo ma teteʻe i le vaega o le Cannabis sativa L. Fula i le 1988; 12: 361-71. Vaʻai faʻamatala.
  79. Valvassori SS, Elias G, de Souza B, et al. Aʻafiaga o le cannabidiol i luga o amphetamine-faʻaosoina oxidative mamafa augatupulaga i se manu faʻatusa o mania. J Psychopharmacol 2011; 25: 274-80. Vaʻai faʻamatala.
  80. Esposito G, Scuderi C, Savani C, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation e ala i le taofiofia o le IL-1beta ma le iNOS faʻaaliga. Br J Pharmacol 2007; 151: 1272-9. Vaʻai faʻamatala.
  81. Esposito G, De Filippis D, Maiuri MC, et al. Cannabidiol taofiofia le faʻaaogaina o le nitric oxide synthase protein faʻamatalaga ma le nitric oxide gaosiga i le beta-amyloid faʻaosofia neuron PC12 e ala i le p38 MAP kinase ma le NF-kappaB auai. Neurosci Lett 2006; 399 (1-2): 91-5. Vaʻai faʻamatala.
  82. Iuvone T, Esposito G, De Filippis D, et al. Cannabidiol: o se faʻamoemoe fou vailaʻau mo neurodegenerative faʻaletonu? CNS Neurosci Ther 2009; 15: 65-75. Vaʻai faʻamatala.
  83. Bisogno T, Di Marzo Y. O le matafaioi a le endocannabinoid system i le gasegase o Alzheimer: mea moni ma mafaufauga. Curr Pharm Des 2008; 14: 2299-3305. Vaʻai faʻamatala.
  84. Zuardi AW. Cannabidiol: mai le le toaga cannabinoid i se vailaʻau ma lautele fusi o gaioiga. Rev Bras Psiquiatr 2008; 30: 271-80. Vaʻai faʻamatala.
  85. Izzo AA, Borelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: fou togafitiga togafitiga mai se anamua laʻau. Faʻalauiloaina Pharmacol Sci 2009; 30: 515-27. Vaʻai faʻamatala.
  86. Booz GW. Cannabidiol o se faʻataʻitaʻiga togafitiga faʻafuaseʻi mo le faʻaititia o le aʻafiaga o le fulafula luga faʻafitauli oxidative. Free Radic Biol Med 2011; 51: 1054-61. Vaʻai faʻamatala.
  87. Filifili JT. Faʻamalieina gaioiga o le cannabis e faʻatatau i lona delta'-trans-tetrahydrocannabinol ma le cannabidiol mea. Br J Pharmacol 1981; 72: 649-56. Vaʻai faʻamatala.
  88. Monti JM. Hypnoticlike effects o le cannabidiol i le isumu. Psychopharmacology (Berl) 1977; 55: 263-5. Vaʻai faʻamatala.
  89. Karler R, Turkanis SA. Togafitiga togafiti cannabinoid: anticonvulsant gaioiga ma toso ese le fiafia i isumu. Br J Pharmacol 1980; 68: 479-84. Vaʻai faʻamatala.
  90. Karler R, Cely W, Turkanis SA. O le anticonvulsant gaioiga o cannabidiol ma cannabinol. Olaga Sci 1973; 13: 1527-31. Vaʻai faʻamatala.
  91. Consroe PF, Wokin AL. Anticonvulsant fegalegaleai o cannabidiol ma ethosuximide i isumu. J Pharm Pharmacol 1977; 29: 500-1. Vaʻai faʻamatala.
  92. Consroe P, Wolkin A. Cannabidiol-antiepilpetic vailaʻau faʻatusatusaga ma fegalegaleaiga i faʻataʻitaʻi faʻatosina faoa i isumu. J Pharmacol Exp Ther 1977; 201: 26-32. Vaʻai faʻamatala.
  93. Carlini EA, Leite JR, Tannhauser M, Berardi AC. Tusi: Cannabidiol ma Cannabis sativa upu puipuia puipuia isumu ma isumu faasaga i faʻalavelave faʻafuaseʻi. J Pharm Pharmacol 1973; 25: 664-5. Vaʻai faʻamatala.
  94. Cryan JF, Markou A, Lucki I. Iloiloina gaoioiga antidepressant i rodents: talu ai nei atinae ma lumanaʻi manaʻoga. Faʻalauiloaina Pharmacol Sci 2002; 23: 238-45. Vaʻai faʻamatala.
  95. El-Alfy AT, Ivey K, Robinson K, et al. Antidepressant-pei aafiaga o delta9-tetrahydrocannabinol ma isi cannabinoids vavae ese mai Cannabis sativa L. Pharmacol Biochem Behav 2010; 95: 434-42. Vaʻai faʻamatala.
  96. Resstel LB, Tavares RF, Lisboa SF, et al. 5-HT1A taliaina o loʻo aʻafia i le faʻamalosia e le cannabidiol o amioga ma tali o le fatu i tali atuatuvale i isumu. Br J Pharmacol 2009; 156: 181-8. Vaʻai faʻamatala.
  97. Granjeiro EM, Gomes FV, ​​Guimaraes FS, et al. Aʻafiaga o intracisternal pulega o le cannabidiol luga o le fatu fatu ma amioga tali i tiga matuia taofiofia. Pharmacol Biochem Behav 2011; 99: 743-8. Vaʻai faʻamatala.
  98. Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, et al. Cannabidiol, o se sui o Cannabis sativa, suia le moe i isumu. FEBS Lett 2006; 580: 4337-45. Vaʻai faʻamatala.
  99. De Filippis D, Esposito G, Cirillo C, et al. Cannabidiol faʻaititia le manava pupuga e ala i le faʻatonutonuina o neuroimmune au. PLoS Tasi 2011; 6: e28159. Vaʻai faʻamatala.
  100. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Faʻatulagaina o mediotemporal ma ventrostriatal galuega i tagata e Delta9-tetrahydrocannabinol: o se neural faʻavae mo aʻafiaga o Cannabis sativa i le aʻoaʻoina ma le mafaufau. Arch Gen Psychiatry 2009; 66: 442-51. Vaʻai faʻamatala.
  101. Dalton WS, Martz R, Lemberger L, et al. Aafiaga o le cannabidiol i aafiaga delta-9-tetrahydrocannabinol. Clin Pharmacol Ther 1976; 19: 300-9. Vaʻai faʻamatala.
  102. Guimaraes VM, Zuardi AW, Del Bel EA, Guimaraes FS. Cannabidiol faʻateleina Fos faʻaaliga i le nucleus accumbens ae le o le dorsal striatum. Olaga Sci 2004; 75: 633-8. Vaʻai faʻamatala.
  103. Moreira FA, Guimaraes FS. Cannabidiol taofiofia le hyperlocomotion faʻaosofia e psychomimetic vailaʻau i isumu. Eur J Pharmacol 2005; 512 (2-3): 199-205. Vaʻai faʻamatala.
  104. Long LE, Chesworth R, Huang XF, et al. O se faʻatusatusaga amioga o matuitui ma masani Delta9-tetrahydrocannabinol ma cannabidiol i C57BL / 6JArc isumu. Int J Neuropsychopharmacol 2010; 13: 861-76. Vaʻai faʻamatala.
  105. Zuardi AW, Rodriguez JA, Cunha JM. Aʻafiaga o le cannabidiol i manu faʻatusa vaʻaia o antipsychotic gaoioiga. Psychopharmacology (Berl) 1991; 104: 260-4. Vaʻai faʻamatala.
  106. Malone DT, Jongejan D, Taylor DA. Cannabidiol suia le faʻaititia o fegalegaleaiga lautele faia e ala maualalo tui Delta-tetrahydrocannabinol i isumu. Pharmacol Biochem Behav 2009; 93: 91-6. Vaʻai faʻamatala.
  107. Schubart CD, Sommer IE, Fusar-Poli P, et al. Cannabidiol o se mafai togafitiga mo psychosis. Eur Neuropsychopharmacol 2014; 24: 51-64. Vaʻai faʻamatala.
  108. Campos AC, Moreira FA, Gomes FV, ​​et al. Tele metotia aofia ai i le tele-fusi fualaʻau togafitiga gafatia o cannabidiol i faʻafitauli o le mafaufau. Philos Trans R Soc Lond B Biol Sci 2012; 367: 3364-78. Vaʻai faʻamatala.
  109. Fusar-Poli P, Allen P, Bhattacharyya S, et al. Faʻatulagaina o le lelei fesoʻotaʻiga i le taimi o faʻagasologa o lagona e Delta 9-tetrahydrocannabinol ma cannabidiol. Int J Neuropsychopharmacol 2010; 13: 421-32. Vaʻai faʻamatala.
  110. Casarotto PC, Gomes FV, ​​Resstel LB, Guimaraes FS. Cannabidiol taofiofia aafiaga i le maamora tanu amioga: aʻafia o CB1 taliaina. Behav Pharmacol 2010; 21: 353-8. Vaʻai faʻamatala.
  111. Uribe-Marino A, Francisco A, Castiblanco-Urbina MA, et al. Aneti-aversive aafiaga o le cannabidiol i luga o le natura fefe-faʻaosofia amioga na faʻaosofia e se amio faʻavae faʻafuaseʻi o osofaʻiga faʻafuaseʻi faʻavae i luga o le vete vs le vao vao Epicrates cenchria crassus finauga faʻafitauli. Neuropsychopharmacology 2012; 37: 412-21. Vaʻai faʻamatala.
  112. Campos AC, Guimaraes FS. Faʻagaoioiga o le 5HT1A taliga e faʻatalanoa aafiaga ole popolevale ole cannabidiol ile PTSD faʻataʻitaʻiga. Behav Pharmacol 2009; 20: S54.
  113. Resstel LB, Joca SR, Moreira FA, et al. Aʻafiaga o le cannabidiol ma diazepam i amioga ma tali o le fatu na mafua mai i le faʻavasega tulaga fefefe i isumu. Behav Brain Res 2006; 172: 294-8. Vaʻai faʻamatala.
  114. Moreira FA, Aguiar DC, Guimaraes FS. Anxiolytic-pei aʻafiaga o cannabidiol i le isumu Vogel feteʻenaʻiga suʻega. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1466-71. Vaʻai faʻamatala.
  115. Onaivi ES, Green MR, Martin BR. Faʻailogaina o vailaʻau faʻasaina o le cannabinoids i le faʻateleina o le paso. J Pharmacol Exp Ther 1990; 253: 1002-9. Vaʻai faʻamatala.
  116. Guimaraes FS, Chairetti TM, Graeff FG, Zuardi AW. Aafiaga faʻafitauli o le cannabidiol i le faʻateleina o le paso-maze. Psychopharmacology (Berl) 1990; 100: 558-9. Vaʻai faʻamatala.
  117. Magen I, Avraham Y, Ackerman Z, et al. Cannabidiol ameliorates faʻaleagaina mafaufau ma afi faʻafitauli i isumu ma bile duct ligation. J Hepatol 2009; 51: 528-34. Vaʻai faʻamatala.
  118. Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol faʻamalieina cardiac faaletonu, faʻamalosia oxidative, fibrosis, ma pupuga ma sela oti feʻilaʻiga ala i diabetic cardiomyopathy. J Am Coll Cardiol 2010; 56: 2115-25. Vaʻai faʻamatala.
  119. El-Remessy AB, Khalifa Y, Ola S, et al. Cannabidiol puipuia neulini neura e ala i le faʻasaoina o le glutamine synthetase gaioiga i le maʻisuka. Mol Vis 2010; 16: 1487-95. Vaʻai faʻamatala.
  120. El-Remessy AB, Al-Shabrawey M, Khalifa Y, et al. Neuroprotective ma toto-retinal papupuni-faʻasao aʻafiaga o cannabidiol i faʻataʻitaʻi suka. Am J Pathol 2006; 168: 235-44. Vaʻai faʻamatala.
  121. Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol faʻamalieina maualuga kulukose-faʻamalosia endothelial sela faʻavevela tali ma faʻalavelave papala. Am J Physiol Heart Circ Physiol 2007; 293: H610-H619. Vaʻai faʻamatala.
  122. Toth CC, Jedrzejewski NM, Ellis CL, Frey WH. Cannabinoid-faʻatulagaina fesuiaʻiga o neuropathic tiga ma microglial faʻaputuputuga i se faʻataʻitaʻiga o murine ituaiga 1 diabetic peripheral neuropathic tiga. Mol Pain 2010; 6:16. Vaʻai faʻamatala.
  123. Aviello G, Romano B, Borrelli F, et al. Aafiaga ole chemopreventive ole non-psychotropic phytocannabinoid cannabidiol i luga ole kanesa ole kolone faʻataʻitaʻi. J Mol Med (Berl) 2012; 90: 925-34. Vaʻai faʻamatala.
  124. Lee CY, Wey SP, Liao MH, et al. O se faʻatusatusaga suʻesuʻega i luga o le cannabidiol-induced apoptosis i murine thymocytes ma EL-4 thymoma sela. Int Immunopharmacol 2008; 8: 732-40. Vaʻai faʻamatala.
  125. Massi P, Valenti M, Vaccani A, et al. 5-Lipoxygenase ma le anandamide hydrolase (FAAH) faʻatosina le antitumor gaioiga o cannabidiol, o se non-psychoactive cannabinoid. J Neurochem 2008; 104: 1091-100. Vaʻai faʻamatala.
  126. Valenti M, Massi P, Bolognini D, et al. Cannabidiol, o le non-psychoactive cannabinoid compound e taofi ai le glioma cell migration tagata ma osofaʻiga. 34th National Congress o le Italia Sosaiete o Fale Talavai 2009.
  127. Torres S, Lorente M, Rodriguez-Fornes F, et al. O se tuufaatasiga preclinical togafitiga o cannabinoids ma temozolomide faasaga glioma. Mol Cancer Ther 2011; 10: 90-103. Vaʻai faʻamatala.
  128. Jacobsson SO, Rongard E, Stridh M, et al. O faʻalagolago i le serum i le tamoxifen ma le cannabinoids i luga ole C6 glioma cell viability. Biochem Pharmacol 2000; 60: 1807-13. Vaʻai faʻamatala.
  129. Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol na mafua ai le oti o sela i polokalame o le kanesa o le susu e ala i le faʻamaopoopoina o le talanoaga i le va o le apoptosis ma le autophagy. Mol Cancer Ther 2011; 10: 1161-72. Vaʻai faʻamatala.
  130. McAllister SD, Murase R, Christian RT, et al. Auala faʻafetaui aafiaga o cannabidiol i luga o le faʻaititia o le kanesa kanesa sela faʻateleina, osofaʻiga, ma metastasis. Fatafata Kanesa o le Fatafata Res 2011, 129: 37-47. Vaʻai faʻamatala.
  131. McAllister SD, Christian RT, Horowitz MP, et al. Cannabidiol o se mea e taofi ai le Id-1 gene faʻaaliga i le teteʻe o le susu kanesa sela. Mol Cancer Ther 2007; 6: 2921-7. Vaʻai faʻamatala.
  132. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor gaioiga o laʻau cannabinoids ma faʻamamafaina i luga o le aʻafiaga o le cannabidiol i luga o le tagata carcinoma susu. J Pharmacol Exp Ther 2006; 318: 1375-87. Vaʻai faʻamatala.
  133. Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol o se ono mafai ai ona avea ma vailaʻau oona. Br J Clin Pharmacol 2013; 75: 303-12. Vaʻai faʻamatala.
  134. Schubart CD, Sommer IE, van Gastel WA, et al. Cannabis ma maualuga mea cannabidiol e fesoʻotaʻi ma le laititi o mafaufauga faʻaletino. Schizophr Res 2011; 130 (1-3): 216-21. Vaʻai faʻamatala.
  135. Englund A, Morrison PD, Nott J, et al. Cannabidiol taofiofia THC-elicited paranoid faʻailoga ma hippocampal-faʻamoemoe manatua le atoatoa. J Psychopharmacol 2013; 27: 19-27. Vaʻai faʻamatala.
  136. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: vailaʻau faʻafomaʻi ma gafatia togafitiga togafitiga i epilepsy ma isi neuropsychiatric faʻaletonu. Epilepsia 2014; 55: 791-802. Vaʻai faʻamatala.
  137. Serpell MG, Notcutt W, Collin C. Sativex taimi umi faʻaaogaina: o se tatala-igoa faʻataʻitaʻiga i tagata mamaʻi ma spasticity ona o le tele sclerosis. J Neurol 2013; 260: 285-95. Vaʻai faʻamatala.
  138. Notcutt W, Langford R, Davies P, et al. O le placebo-pulea, tutusa vaega, faʻasolosolo toesea le suʻesuʻeina o mataupu ma faʻailoga o le spasticity ona o le tele sclerosis o loʻo mauaina umi-umi Sativex (nabiximols). Mult Scler 2012; 18: 219-28. Vaʻai faʻamatala.
  139. Brady CM, DasGupta R, Dalton C, et al. O se suʻesuʻega faʻaavanoaina o vailaʻau faʻavaeina o le cannabis mo le faʻafitauli o le toto i le tele o sclerosis. Mult Scler 2004; 10: 425-33. Vaʻai faʻamatala.
  140. Kavia RB, De Ridder D, Constantinescu CS, et al. Faʻataʻitaʻia faʻataʻitaʻia le faʻataʻitaʻia o le Sativex e togafitia ai le faʻaititia o le detrusor i le tele o sclerosis. Mult Scler 2010; 16: 1349-59. Vaʻai faʻamatala.
  141. Wade DT, Makela PM, House H, et al. Faʻaaoga umi o se vailaʻau faʻavae vailaʻau i le spasticity ma isi faʻailoga i le tele sclerosis. Mult Scler 2006; 12: 639-45. Vaʻai faʻamatala.
  142. Novotna A, Mares J, Ratcliffe S, et al. A randomized, lua-tauaso, placebo-pulea, tutusa-kulupu, faʻatamaoaigaina-mamanu suʻesuʻega o nabiximols * (Sativex), pei faʻaopopo-i togafitiga, i mataupu ma refactory spasticity mafuaʻaga e tele sclerosis. Eur J Neurol 2011; 18: 1122-31. Vaʻai faʻamatala.
  143. Vaaiga aoao. 'Upega tafaʻilagi a le GW Fale Talavai.Avanoa i le: http://www.gwpharm.com/about-us-overview.aspx Avanoa: Me 31, 2015.
  144. Cannabidiol Nei Ua Faʻaalia I Meaʻai Meaʻai. 'Upega tafaʻilagi e fai ma vailaʻau. https://naturalmedicines.therapeuticresearch.com/news/news-items/2015/march/cannabidiol-now-showing-up-in-dietary-supplements.aspx. (Avanoa ia Me 31, 2015).
  145. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Aafiaga o ipsapirone ma cannabidiol i luga o tagata popolevale faʻataʻitaʻiga. J Psychopharmacol 1993; 7 (1 Faʻaopopo): 82-8. Vaʻai faʻamatala.
  146. Leighty EG, Fentiman AF Jr, Foltz RL. O metabolites umi na taofia o delta9- ma delta8-tetrahydrocannabinols ua faʻailoa mai o le fatty acid conjugates. Res Commun Chem Pathol Pharmacol 1976; 14: 13-28. Vaʻai faʻamatala.
  147. Samara E, Bialer M, Mechoulam R. Pharmacokinetics o le cannabidiol i maile. Lafoaʻiga o Metab Vailaʻau 1988; 16: 469-72. Vaʻai faʻamatala.
  148. Consroe P, Sandyk R, Snider SR. Tatala le iloiloga o le cannabidiol i faʻaletonu o gaioiga a le dystonic. Int J Neurosci 1986; 30: 277-82. Vaʻai faʻamatala.
  149. Crippa JA, Derenusson GN, Ferrari TB, et al. Faʻavae neural o le popolevaleʻafiaga o le cannabidiol (CBD) i le lautele lautele faʻafitauli o le popolevale lautele: o se uluaʻi lipoti. J Psychopharmacol 2011; 25: 121-30. Vaʻai faʻamatala.
  150. Bornheim LM, Everhart ET, Li J, Correia MA. Faʻailogaina o le cannabidiol-mediated cytochrome P450 le faʻagaoioia. Biochem Pharmacol 1993; 45: 1323-31. Vaʻai faʻamatala.
  151. Harvey DJ. Mitiia, tufatufaina, ma biotransformation o le cannabinoids. Marijuana ma Vailaau. 1999; 91-103.
  152. Yamaori S, Ebisawa J, Okushima Y, et al. Malosiaga taofiofi o le tagata cytochrome P450 3A isoforms e le cannabidiol: matafaioi a phenolic hydroxyl kulupu i le resorcinol ita. Olaga Sci 2011; 88 (15-16): 730-6. Vaʻai faʻamatala.
  153. Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, o le tele o le phytocannabinoid, o se malosiʻaga taofiofi atypical mo CYP2D6. Fualaʻau Faʻasaina o Metab 2011; 39: 2049-56. Vaʻai faʻamatala.
  154. Yamaori S, Maeda C, Yamamoto I, Watanabe K.Faʻafitia le taofiofia o le tagata cytochrome P450 2A6 ma le 2B6 e le tele o le phytocannabinoids. Forensic Toxicol 2011; 29: 117-24.
  155. Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Faʻailogaina o sili atu phytocannabinoids, cannabidiol ma cannabinol, e pei o isoform-filifilia filifilia malosi o tagata CYP1 enzymes. Biochem Pharmacol 2010; 79: 1691-8. Vaʻai faʻamatala.
  156. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol mo le togafitia o psychosis i le faʻamaʻi o Parkinson. J Psychopharmacol 2009; 23: 979-83. Vaʻai faʻamatala.
  157. Morgan CJ, Das RK, Joye A, et al. Cannabidiol faʻaititia le ulaula taumafa i tagata ulaula tapaʻa: faʻamatalaga muamua. Addict Behav 2013; 38: 2433-6. Vaʻai faʻamatala.
  158. Pertwee RG. O le eseese CB1 ma CB2 talimalo talavai o le tolu laau cannabinoids: delta9-tetrahydrocannabinol, cannabidiol ma delat9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215. Vaʻai faʻamatala.
  159. Leweke FM, Kranaster L, Pahlisch F, et al. Le aoga ole cannabidiol ile togafitia ole schizophrenia - ose auala faʻaliliuga. Schizophr Bull 2011; 37 (Suppl 1): 313.
  160. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol faʻalauteleina le anandamide faʻailo ma faʻaitiitia faʻafitauli psychotic o le schizophrenia. Faʻaliliu Psychiatry 2012; 2: e94. Vaʻai faʻamatala.
  161. Carroll CB, Bain PG, Teare L, et al. Cannabis mo le dyskinesia ile faʻamaʻi Parkinson: ose faʻasolosolo faʻalua-tauaso suʻesuʻe suʻesuʻega. Neurology 2004; 63: 1245-50. Vaʻai faʻamatala.
  162. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol faʻaititia le popolevale faʻamalosia e simulated tagata lautele tautala i togafitiga-naif social social phobia tagata mamaʻi. Neuropsychopharmacology 2011; 36: 1219-26. Vaʻai faʻamatala.
  163. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, o le Cannabis sativa constituent, o se vailaʻau antipsychotic. Braz J Med Biol Res 2006; 39: 421-9. Vaʻai faʻamatala.
  164. Yadav V, Bever C Jr, Bowen J, et al. Aotelega o faʻamaoniga-faʻavae taiala: lagolago ma isi vailaʻau i tele sclerosis: lipoti o le taʻiala atinaʻe soakomiti o le American Academy of Neurology. Neurology 2014; 82: 1083-92. Vaʻai faʻamatala.
  165. Tr Assembly B, Sherman M. Faʻalua-tauaso falemaʻi suʻesuʻega o le cannabidiol o se tulaga lua anticonvulsant. Marijuana '90 Konafesi Faʻavaomalo i luga o Cannabis ma Cannabinoids 1990; 2: 5.
  166. Srivastava, M. D., Srivastava, B. I., ma Brouhard, B. Delta9 tetrahydrocannabinol ma cannabidiol suia cytokine gaosia e tagata puipuia sela. Immunopharmacology 1998; 40: 179-185. Vaʻai faʻamatala.
  167. Cunha, JM, Carlini, EA, Pereira, AE, Ramos, OL, Pimentel, C., Gagliardi, R., Sanvito, WL, Lander, N., ma Mechoulam, R. Faʻataʻitaʻiina taimi o cannabidiol i soifua maloloina volenitia ma tagata gasegase epileptic . Fomaʻi vailaʻau 1980; 21: 175-185. Vaʻai faʻamatala.
  168. Carlini EA, Cunha JM. Hypnotic ma antiepileptic aafiaga o le cannabidiol. J Clin Pharmacol 1981; 21 (8-9 Suppl): 417S-27S. Vaʻai faʻamatala.
  169. Zuardi, A. W., Shirakawa, I., Finkelfarb, E., ma Karniol, I. G. Gaioiga o cannabidiol i luga o le atuatuvale ma isi aafiaga na gaosia e le delta 9-THC i mataupu masani. Psychopharmacology (Berl) 1982; 76: 245-250. Vaʻai faʻamatala.
  170. Ames, F. R. ma Cridland, S. Anticonvulsant aafiaga o le cannabidiol. S.Afr.Med.J. 1-4-1986; 69:14. Vaʻai faʻamatala.
  171. Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., ma Hollister, L. E. Tasi-inumaga kinetics o deuterium-igoa cannabidiol i le tagata ina ua uma ulaula ma inisetiina pulega. Biomed.Environ Masini Spectrom. 1986; 13: 77-83. Vaʻai faʻamatala.
  172. Wade, D. T., Collin, C., Stott, C., ma Duncombe, P. Meta-auiliiliga o le aoga ma le saogalemu o Sativex (nabiximols), i luga o spasticity i tagata e tele sclerosis. Mult.Scler. 2010; 16: 707-714. Vaʻai faʻamatala.
  173. Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Novakova, I ., Zapletalova, O., Pikova, J., ma Ambler, Z. O le faʻalua-tauaso, faʻasolosolo, placebo-pulea, tutusa-kulupu suʻesuʻega o Sativex, i mataupu ma faʻailoga o spasticity ona o le tele sclerosis. Neurol.Res. 2010; 32: 451-459. Vaʻai faʻamatala.
  174. Crippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., ma Fusar-Poli, P. Cannabis ma le popole: o se toe iloiloga faigata o le molimau. Hum. Psychopharmacol. 2009; 24: 515-523. Vaʻai faʻamatala.
  175. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., ma Schram, K. Faʻatautaia faʻataʻitaʻi faʻafomaʻi o le cannabidiol i le faamaʻi o Huntington. Pharmacol Biochem.Behav. 1991; 40: 701-708. Vaʻai faʻamatala.
  176. Harvey, D. J., Samara, E., ma Mechoulam, R. Faʻatusatusaga metabolism o le cannabidiol i le maile, isumu ma le tamaloa. Pharmacol Biochem.Behav. 1991; 40: 523-532. Vaʻai faʻamatala.
  177. Collin, C., Davies, P., Mutiboko, I. K., ma Ratcliffe, S. Faʻataʻitaʻia faʻatonutonuina suʻesuʻega o vailaʻau-faʻavae vailaʻau i le spasticity mafua mai i le tele sclerosis. Eur.J.Neurol. 2007; 14: 290-296. Vaʻai faʻamatala.
  178. Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., ma Parolaro, D. O le non-psychoactive cannabidiol e mafua ai le faʻagaoioia o le caspase ma le faʻamamafa o le oxidative i sela o tagata glioma. Cell Mol.Life Sci. 2006; 63: 2057-2066. Vaʻai faʻamatala.
  179. Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., ma Gallily, R. Cannabidiol maualalo le maua i le maʻisuka i isumu le-suka suka. Taofiofia 2006; 39: 143-151. Vaʻai faʻamatala.
  180. Watzl, B., Scuderi, P., ma Watson, R. R. Marijuana vaega faʻaosofia tagata peripheral toto mononuclear sela faʻalilolilo o interferon-gamma ma taofia interleukin-1 alpha in vitro. Int J Immunopharmacol. 1991; 13: 1091-1097. Vaʻai faʻamatala.
  181. Consroe, P., Kennedy, K., ma Schram, K. Assay o le plasma cannabidiol e ala i le capillary gas chromatography / ion trap mass spectroscopy i le maeʻa ai o le maualuga o fuataga faia i aso uma i le tautala i tagata. Pharmacol Biochem.Behav. 1991; 40: 517-522. Vaʻai faʻamatala.
  182. Barnes, M. P. Sativex: aoga faʻamalositino ma faʻapalepale i le togafitia o faʻailoga o le tele sclerosis ma neuropathic tiga. Tomai Faʻapitoa. Faʻamau. 2006; 7: 607-615. Vaʻai faʻamatala.
  183. Wade, D. T., Makela, P., Robson, P., House, H., ma Bateman, C. E maua i vailaʻau faʻavae vailaʻau vailaau vailaʻau pe faʻapitoa aafiaga i faʻailoga i tele sclerosis? O se faʻalua-tauaso, faʻasolosolo, placebo-pulea suesuega i 160 tagata mamaʻi. Mult.Scler. 2004; 10: 434-441. Vaʻai faʻamatala.
  184. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., ma Izzo, AA Neuroprotective aafiaga o le cannabidiol, o se le psychoactive vaega mai Cannabis sativa, i beta-amyloid-faʻaosofia oʻona i sela PC12. J Neurochem. 2004; 89: 134-141. Vaʻai faʻamatala.
  185. Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., ma Parolaro, D. Antitumor aafiaga o le cannabidiol, o se nonpsychoactive cannabinoid, i luga o tagata glioma sela laina. J Pharmacol Exp.Ther. 2004; 308: 838-845. Vaʻai faʻamatala.
  186. Crippa, JA, Zuardi, AW, Garrido, GE, Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, PM, Hallak, JE, McGuire, PK, ma Filho, Busatto G. Aafiaga o le cannabidiol (CBD) i luga ole faʻaitete o le toto o le cerebral. Neuropsychopharmacology 2004; 29: 417-426. Vaʻai faʻamatala.
  187. Wade, D. T., Robson, P., House, H., Makela, P., ma Aram, J. O se uluaʻi faʻatonutonu suʻesuʻega e faʻamautinoa ai pe o le atoa-totoina vailaʻau vailaʻau mafai ona faʻaleleia le mafai ona togafitia faʻailoga o neura. Togafitiga. 2003; 17: 21-29. Vaʻai faʻamatala.
  188. Covington TR, ma isi. Tusitaulima o Fualaʻau Faʻatonu. 11th lomiga. Uosigitone, DC: American Farmasi Association, 1996.
Toe iloiloga - 12/18/2020

Matou Te Fautua Atu

Vailaau mo Tagata ma Ulcerative Colitis
Soifua Maloloina

Vailaau mo Tagata ma Ulcerative Colitis

FaatomuagaO le ulcerative coliti o e ituaiga o faʻamaʻi o le manava o le manava (IBD) e tele na afaina ai le faʻamaʻi (ga tele). E ono faʻatupuina e e tali le talafeagai mai le tino o lou tino. E ui ...
O le a le Suʻega Eseesega?
Soifua Maloloina

O le a le Suʻega Eseesega?

A e ailia le faʻalogo mo e faʻafitauli tau oifua maloloina, e faʻaaogaina e lau fomaʻi le faʻamaoniga e iloa ai le tulaga e ono mafua ai au faʻailoga.I le avea ai o e vaega o lenei gaioiga, o le a lat...